 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 June 1994 | Volume 120 Issue 11 | Pages 903-912
Objective: To determine if low-dose involved field radiation after complete remission induction with chemotherapy is effective in preventing relapse and improving survival in patients with stage III or IV Hodgkin disease.
Design: A randomized controlled trial with a median follow-up time of 8.1 years.
Setting: A Southwest Oncology Group multi-institutional study. Patients were entered from university- and community-based practices.
Patients: 278 adults with clinical or pathologic stage III or IV Hodgkin disease, who achieved complete responses after 6 cycles of MOP-BAP (nitrogen mustard, vincristine, prednisone, bleomycin, doxorubicin, and procarbazine) and who agreed to be randomly assigned to either radiation or no further treatment.
Intervention: Patients were assigned to either no further treatment or low-dose radiation to all initially involved sites (radiation dose, 2000 cGy to lymph node areas and 1000 to 1500 cGy to other involved organ sites).
Measurements: Differences in remission duration, relapse-free survival, and survival.
Results: Remission duration, relapse-free survival, and overall survival were similar for the two groups (P = 0.09, P > 0.2, and P = 0.14, respectively). Factors that predicted shorter remission duration in a multivariate analysis were nodular sclerosis histology, bulky disease, and receipt of less than 85% of planned chemotherapy. Low-dose radiation improved remission duration in the subgroups of patients with nodular sclerosis and bulky disease. For the 169 patients with nodular sclerosis, the 5-year remission-duration estimate was 82% for the low-dose radiation group and 60% for the no further treatment group (P = 0.002). For all patients with bulky disease, the 5-year remission-duration estimate was 75% for the low-dose radiation group and 57% for the no further treatment group (P = 0.05). No difference in overall survival was noted between low-dose radiation and no further treatment in all patients or major subgroups. The 5-year survival was 86% for all patients who had a complete response as well as for patients in the nodular sclerosis subgroup.
Conclusions: Low-dose involved field radiation after MOP-BAP chemotherapy in patients with stage III or IV Hodgkin disease did not prolong remission duration or overall survival in randomized patients. However, remission duration was prolonged in several subgroups of patients, most prominently in those with nodular sclerosis histology.
Author and Article Information
From the University of Kansas Medical Center, Kansas City, Kansas; the Southwest Oncology Group Statistical Center, Seattle, Washington; the University of Arizona Cancer Center, Tucson, Arizona; Henry Ford Hospital, Detroit, Michigan; the University of Oklahoma Health Science Center, Oklahoma City, Oklahoma; the University of Mississippi Medical Center, Jackson, Mississippi; the University of Texas Health Science Center at San Antonio, San Antonio, Texas; Loyola University Stritch School of Medicine, Maywood, Illinois.
ARTICLE
Low-Dose Involved Field Radiation after Chemotherapy in Advanced Hodgkin Disease: A Southwest Oncology Group Randomized Study
Requests for Reprints: Publications, Southwest Oncology Group (SWOG-7808), Operations Office, 14980 Oµm Drive, San Antonio, TX 78229-6197.
Grant Support: In part by grants from the Public Health Service Cooperative Agreement awarded by the National Cancer Institute, Department of Health Services as follows: CA-12644, CA-37429, CA-13612, CA-04915, CA-35995, CA-16385, CA-22433, CA-46282, CA-13238, CA-04919, CA-36020, CA-03389, CA-20319, CA-37981, CA-46113, CA-03096, CA-32734, CA-28862, CA-04920, CA-27057, CA-35431, CA-22411, CA-35438, CA-35090, CA-35262, CA-35274, CA-35261, CA-35176, CA-35117, CA-12213, CA-35996, CA-35158, CA-37445, CA-35119, CA-14028, CA-35178, CA-35109, and CA-32102.
This article has been cited by other articles:
|
|
 |
|
  J Franklin, A Pluetschow, M Paus, L Specht, A-P Anselmo, A Aviles, G Biti, T Bogatyreva, G Bonadonna, C Brillant, et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials Ann. Onc., December 1, 2006; 17(12): 1749 - 1760. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Carde In Reply J. Clin. Oncol., July 10, 2006; 24(20): 3309 - 3310. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Ferme, N. Mounier, O. Casasnovas, P. Brice, M. Divine, A. Sonet, F. Bouafia, A. Bastard-Stamatoullas, D. Bordessoule, L. Voillat, et al. Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) Blood, June 15, 2006; 107(12): 4636 - 4642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Laskar, T. Gupta, S. Vimal, M.A. Muckaden, T.K. Saikia, S.K. Pai, K.N. Naresh, and K.A. Dinshaw Consolidation Radiation After Complete Remission in Hodgkin's Disease Following Six Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Chemotherapy: Is There a Need? J. Clin. Oncol., January 1, 2004; 22(1): 62 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Diehl Chemotherapy or Combined Modality Treatment: The Optimal Treatment for Hodgkin's Disease J. Clin. Oncol., January 1, 2004; 22(1): 15 - 18. [Full Text] [PDF]
|
|
|
|
|
|
B. M.P. Aleman, A. W. van den Belt-Dusebout, W. J. Klokman, M. B. van't Veer, H. Bartelink, and F. E. van Leeuwen Long-Term Cause-Specific Mortality of Patients Treated for Hodgkin's Disease J. Clin. Oncol., September 15, 2003; 21(18): 3431 - 3439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M.P. Aleman, J. M.M. Raemaekers, U. Tirelli, R. Bortolus, M. B. van 't Veer, M. L.M. Lybeert, J. J. Keuning, P. Carde, T. Girinsky, R. W.M. van der Maazen, et al. Involved-Field Radiotherapy for Advanced Hodgkin's Lymphoma N. Engl. J. Med., June 12, 2003; 348(24): 2396 - 2406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ikeda Quality Assurance Activities in Radiotherapy Jpn. J. Clin. Oncol., December 1, 2002; 32(12): 493 - 496. [Full Text] [PDF]
|
|
|
|
|
|
A. K. Ng, M. P. Bernardo, E. Weller, K. H. Backstrand, B. Silver, K. C. Marcus, N. J. Tarbell, J. Friedberg, G. P. Canellos, and P. M. Mauch Long-Term Survival and Competing Causes of Death in Patients With Early-Stage Hodgkin's Disease Treated at Age 50 or Younger J. Clin. Oncol., April 15, 2002; 20(8): 2101 - 2108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. Canellos New Treatments for Advanced Hodgkin's Disease: An Uphill Fight Beginning Close to the Top J. Clin. Oncol., February 1, 2002; 20(3): 607 - 609. [Full Text] [PDF]
|
|
|
|
|
|
S. J. Horning, R. T. Hoppe, S. Breslin, N. L. Bartlett, B. W. Brown, and S. A. Rosenberg Stanford V and Radiotherapy for Locally Extensive and Advanced Hodgkin's Disease: Mature Results of a Prospective Clinical Trial J. Clin. Oncol., February 1, 2002; 20(3): 630 - 637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Connors, E. M. Noordijk, and S. J. Horning Hodgkin's Lymphoma: Basing the Treatment on the Evidence Hematology, January 1, 2001; 2001(1): 178 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ferme, C. Sebban, C. Hennequin, M. Divine, P. Lederlin, J. Gabarre, A. Ferrant, D. Caillot, D. Bordessoule, P. Brice, et al. Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: results of the Groupe d'etudes des Lymphomes de l'Adulte H89 trial Blood, April 1, 2000; 95(7): 2246 - 2252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Horning, J. Williams, N. L. Bartlett, J. M. Bennett, R. T. Hoppe, D. Neuberg, and P. Cassileth Assessment of the Stanford V Regimen and Consolidative Radiotherapy for Bulky and Advanced Hodgkin’s Disease: Eastern Cooperative Oncology Group Pilot Study E1492 J. Clin. Oncol., March 1, 2000; 18(5): 972 - 972. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Ng, J. C. Weeks, P. M. Mauch, and K. M. Kuntz Decision Analysis on Alternative Treatment Strategies for Favorable-Prognosis, Early-Stage Hodgkin's Disease J. Clin. Oncol., November 1, 1999; 17(11): 3577 - 3585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Front, R. Bar-Shalom, M. Mor, N. Haim, R. Epelbaum, A. Frenkel, D. Gaitini, G. M. Kolodny, and O. Israel Hodgkin Disease: Prediction of Outcome with 67Ga Scintigraphy after One Cycle of Chemotherapy Radiology, February 1, 1999; 210(2): 487 - 491. [Abstract] [Full Text]
|
|
|
|
|
|
A. C. Aisenberg Problems in Hodgkin's Disease Management Blood, February 1, 1999; 93(3): 761 - 779. [Full Text] [PDF]
|
|
|
|
|
|
A. K. Ng, J. C. Weeks, P. M. Mauch, and K. M. Kuntz Laparotomy Versus No Laparotomy in the Management of Early-Stage, Favorable-Prognosis Hodgkin's Disease: A Decision Analysis J. Clin. Oncol., January 1, 1999; 17(1): 241 - 241. [Abstract] [Full Text] [PDF]
|
|
Article
